Member Info for john389

are sometimes disappearing from this board

Your guess is as good as mine Ceejay.There has been talk on the boards of well over a pound

Ceejay.I don’t think the institutional holders holding over 40% of the stock would settle for being taken out for a joke price when they know the potential! They have a huge say in what this price will go for

Great info Lea and nice to know HVIVO is in very capable hands!

Thanks Lea so could be finding a buyer for the Vaccine through connections?

Ceejay: it would cost them many multiples of the current price if they wait till phase 3 results.Its worth their while to buy now and as the man at the helm said ,he is looking to sell the vaccine in in the next few months. Do you really hold?

Lea what’s the connection with UBS and Deutsche Bank in your post?

Thanks Aim for info. Wonder why the hold up in the license when Alara get theirs

So could one assume that even if licence awarded SAV may not move as well?

That transaction could have been delayed and not reported at the time it actually happened.

Totally agree and with the free float decreasing will only accentuate further rises

They would not be buying if they were not convinced the vaccine will be sold off in my view! Excellent news!

Well the small cap and positive results speak for themselves! Any hint they are in talks about a JV or buyout will multibag this significantly in my opinion

The same sheep will buy when it turns

The word sheep springs to mind!

Pmatlock The reward versus the risk is heavily in our favour at this price in my view and even if it reaches your target price to buy in at 21p lol, not many people who have bought in today myself included will be unduly worried

In your dreams son

Num4 No one in their right mind thinks this will go to £8 but the interesting point is that big companies are still interested and ,with the share price near to lows, scope for a hefty multibag exists and not unreasonably in my opinion!

My message was directed at Num4

You really think statistical analysis of results about improving end points is of interest to those sufferers who have benefited from the trial and some even going into remission.The percentage who benefited was considerable and two much to be a coincidence in my view.Drug companies interest will be enough to provide buying momentum in my opinion